

# Vaccine-poor Germans shunning AstraZeneca jab

18 February 2021, by Deborah Cole



A shut cafe in Munich, Germany. Countries are relying on vaccines to tame the pandemic, but some Germans have shunned the AstraZeneca jab after confusion over guidance for administering it

Doctors and public health officials pleaded with Germans Thursday to take up AstraZeneca vaccines against the coronavirus after muddled communication about the efficacy of the British-made jabs hit demand.

Despite a raging debate about a sluggish EU rollout of vaccines, German healthcare facilities have reported several hundred thousand AstraZeneca vials sitting unused and rampant no-shows at scheduled appointments.

Officials in Italy, Austria and Bulgaria were also starting to signal some public resistance to the British vaccine, and France's Health Minister Olivier Veran got the jab live on television to drum up support.

"If you are given the choice between AstraZeneca now or another vaccine in a few months, you should definitely take AstraZeneca now," implored Carsten Watzl, general secretary of the German Society for Immunology.

"Saying the AstraZeneca vaccine is second-class is scientifically and from a public health perspective dead wrong," he told the daily *Augsburger Allgemeine*.

Health Minister Jens Spahn echoed the message, calling all three vaccines approved in the EU—AstraZeneca, BioNTech/Pfizer and Moderna—"safe and effective" despite varying levels of efficacy.

AstraZeneca has been shown to be about 60 percent effective in trials, while studies point to around 95 percent efficacy for the latter two products.

However the British jab has the advantage of not requiring deep-freeze storage, with a regular refrigerator sufficing.



Barrier tape lies on the ground next to bouncers at a children's playground in Munich

## Misleading coverage

The image problem stems largely from confusion

around German guidance last month for the vaccine developed by British-Swedish pharmaceutical firm AstraZeneca in partnership with Oxford University.

Citing a lack of data about efficacy in the elderly, Germany's vaccine commission said AstraZeneca was recommended only for people aged 18 to 64 years old.

The decision had been preceded by contradictory German media coverage about the jab.

Business paper Handelsblatt and Bild daily had reported that efficacy among above-65s was below 10 percent—claims that were firmly rejected by the German government and the company.

Even British Prime Minister Boris Johnson came out to defend the jabs, which have already been widely used in Britain on older people.

But this month South Africa suspended its vaccine rollout after a study found the Oxford/AstraZeneca jab failed to prevent mild and moderate illness caused by a variant found in the country which has since spread to Germany.

Institute for disease control reported.

In the state of Saxony, which has some of Germany's highest infection rates, more than 2,500 available appointments were going unfilled this week, the Red Cross said, citing doubts about the AstraZeneca vaccine as the main cause.

And Brandenburg state surrounding Berlin said it would make the jabs available to police officers, who are lower on the vaccine priority list, because AstraZeneca vials were going unused.

**'Catastrophic communication'**

Spahn said officials were working to make sure none of the precious jabs went to waste, as a poll for the Tagesspiegel newspaper showed that only one in three Germans under the age of 65 was ready to get the AstraZeneca vaccine rather than wait for another product.

With more than 60 percent of Germans saying they want to get vaccinated, opposition politicians blamed the government for undermining faith in AstraZeneca.

**Covid-19 vaccines**

Vaccines authorised by one or more medical agencies

LABORATORIES	Technology	Clinical efficacy	Storage temperature	Time between doses
Pfizer /BioNTech	Messenger ARN	95%	-70°C	21 jours
Moderna	Messenger ARN	94.1%	-20°C	28
Gamaleya (Sputnik V)	Viral vector	91.6%	2 to 8°C	21
Oxford /AstraZeneca	Viral vector	82.4%*	2 to 8°C	90
Sinopharm	Inactivated virus	79.3%	2 to 8°C	21
Sinovac (CoronaVac)	Inactivated virus	50.38 to 100%**	2 to 8°C	14

\*according to a study published by Oxford University Feb 2  
 \*\*results in countries where the vaccine was tested, in the absence of published clinical trials  
 Sources: WHO laboratories, Vaccines from Bharat Biotech and CanSino Biologicals laboratories have also been approved in some countries



Graphic on Covid-19 vaccines authorised by one or more medical agencies

A health professional poses with a test cassette used for an antigen rapid test for Covid-19 at a testing center in Berlin

The mixed messaging had a lasting impact.

Nearly 740,000 AstraZeneca doses have been delivered to Germany's 16 states but only 107,000 had been used by Thursday, the Robert Koch

Kordula Schulz-Asche of the Greens party told Welt daily that scepticism was spreading even among

healthcare givers "which can be blamed on a truly catastrophic communication strategy" from Berlin.

Chancellor Angela Merkel has pledged that all Germans will receive an offer for their first jab by September 21 at the latest.

But with production problems and logistical hiccups slowing the vaccine drive, officials are increasingly telling Germans that beggars can't be choosers when it comes to which shot they get.

Germany has reported some success in reducing new infections thanks to a three-month partial lockdown. On Thursday, it recorded 10,207 new cases of COVID-19 in the previous 24 hours and 534 deaths.

But the decrease in new cases is stagnating and highly infectious virus variants are on the march, with the UK mutation now accounting for more than one in five infections.

And as of Wednesday, only 3.6 percent of the population had received the first of the necessary two jabs of any vaccine.

© 2021 AFP

APA citation: Vaccine-poor Germans shunning AstraZeneca jab (2021, February 18) retrieved 27 September 2022 from <https://medicalxpress.com/news/2021-02-vaccine-poor-germans-shunning-astrazeneca-jab.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*